Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis
Open Access
- 29 July 2003
- journal article
- other
- Published by Springer Nature in Leukemia
- Vol. 17 (8) , 1674-1677
- https://doi.org/10.1038/sj.leu.2403025
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcomeLeukemia, 2003
- Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720Blood, 2002
- The Role of Drug Efflux Pumps in Acute Myeloid LeukemiaLeukemia & Lymphoma, 2002
- Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemiaLeukemia, 2001
- Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemiaBlood, 2000
- P-Glycoprotein Protects Leukemia Cells Against Caspase-Dependent, but not Caspase-Independent, Cell DeathBlood, 1999
- Immunophenotyping Investigation of Minimal Residual Disease Is a Useful Approach for Predicting Relapse in Acute Myeloid Leukemia PatientsBlood, 1997